- ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
- Glajzer J, Castillo-Tong DC, Richter R, Vergote I, Kulbe H, Vanderstichele A, Ruscito I, Trillsch F, Mustea A, Kreuzinger C, Gourley C, Gabra H, Taube ET, Dorigo O, Horst D, Keunecke C, Baum J, Angelotti T, Sehouli J, Braicu EI.
- Ann Surg Oncol. 2022 Nov 5. doi: 10.1245/s10434-022-12681-z. Epub ahead of print.
- PMID: 36335272
- PubMed abstract
- Source abstract
- Review
•• Original research:
Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
- PMID: 36085390
- PubMed abstract
- Free Full Text
- Prognostic impact of germline BRCA1/2 pathogenic variants in breast cancer.
- Corso G, Girardi A, Calvello M, Gandini S, Gaeta A, Marabelli M, Magnoni F, Veronesi P, Guerrieri-Gonzaga A, Bonanni B.
- Breast Cancer Res Treat. 2022 Nov 4. doi: 10.1007/s10549-022-06776-0. Epub ahead of print.
- PMID: 36331686
- PubMed abstract
- Source abstract
- A common IGF1R gene variant predicts later life breast cancer risk in women with preeclampsia.
- Powell M, Fuller S, Gunderson E, Benz C.
- Breast Cancer Res Treat. 2022 Nov 4. doi: 10.1007/s10549-022-06789-9. Epub ahead of print.
- PMID: 36331687
- PubMed abstract
- Detection of microsatellite instability high (MSI-H) status by targeted plasma-based genotyping in metastatic breast cancer.
- Vidula N, Lipman A, Kato S, Weipert C, Hesler K, Azzi G, Elkhanany A, Juric D, Rodriguez E, Faulkner C, Makhlouf P, Price K, O'Shaughnessy J, Bardia A.
- NPJ Breast Cancer. 2022 Nov 4;8(1):117. doi: 10.1038/s41523-022-00490-2.
- PMID: 36333333
- PubMed abstract
- Characteristics of BRCA2 Mutated Prostate Cancer at Presentation.
- Han H, Park CK, Cho NH, Lee J, Jang WS, Ham WS, Choi YD, Cho KS.
- Int J Mol Sci. 2022 Nov 3;23(21):13426. doi: 10.3390/ijms232113426.
- PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology.
- Miglietta F, Cinquini M, Dieci MV, Cortesi L, Criscitiello C, Montemurro F, Del Mastro L, Zambelli A, Biganzoli L, Levaggi A, Piane CD, Marchiò C, Calabrese M, Fortunato L, Franco P, Meduri B, Fittipaldo VA, Gori S.
- Breast. 2022 Oct 29:S0960-9776(22)00179-5. doi: 10.1016/j.breast.2022.10.014. Epub ahead of print.
- Meta-Analysis
- Free Full Text
- Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in the United States, Europe, and Israel.
- Mahtani R, Niyazov A, Lewis K, Rider A, Massey L, Arondekar B, Lux MP.
- Adv Ther. 2022 Oct 28. doi: 10.1007/s12325-022-02302-2. Epub ahead of print.
- PMID: 36333567
- PubMed abstract
- PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Whom to Treat?
- Loguidice CT.
- OncLive. 2022 Oct 28.
- Review
- Free Full Text
- Adolescent Triple-negative Breast Cancer with Germline Pathogenic Variants in both BRCA1 and TP53 Genes: A Case Report.
- Chen D, Yuan M, Zhang Y, Zhang C, Wan D.
- Front Oncol. 2022 Oct 26;12:970641. doi: 10.3389/fonc.2022.970641.
- Case report
- Free Full Text